Abstract
BackgroundPulmonary spindle cell carcinoma (PSCC) is a rare type of non-small cell lung cancer (NSCLC). The prognostic influent factors and therapeutic methods of PSCC are unclear, for there are only some case reports or small samples’ analysis. This study aims to find prognosis related factors of PSCC, develop and validate a nomogram to predict their survival probability.MethodsThe Surveillance, Epidemiology, and End Results (SEER) 18 Registries database (2000–2018) was searched to study PSCC. According to diagnosed time, data was divided into primary cohort (2000–2015) and validation cohort (2016–2018), both followed until December 31 2018. Chosen by Least Absolute Shrinkage and Selection Operator (LASSO) regression, age, sex, stage, surgery, chemotherapy, N, size and history of malignancy were taken out as predictive variables. The primary cohort was used to develop a nomogram to predict 1-, 3- and 5-year overall survival (OS) probability, and be validated by the validation cohort using concordance index (C-index) and calibration curves. Both cohorts were used to conduct a Cox regression to find the influential factors on OS of PSCC.ResultsThe nomogram shows a good concordance and discrimination on the prediction of OS, both internal (n=457 and C-index is 0.79) and external validation (n=100 and C-index is 0.76). The median survival time of PSCC is 4 months, with 20.1% OS possibility in 5 years. Multivariate analysis identified patients of older age [hazard ratio (HR), 1.02; 95% confidence interval (CI): 1.01–1.04], larger size of neoplasm (HR, 1.01; 95% CI: 1.01–1.01), M1 (HR, 2.96; 95% CI: 2.17–4.04), N2 (HR, 2.55; 95% CI: 1.81–3.59) or N3 (HR, 2.99; 95% CI: 1.58–5.66), regional stages (HR, 2.11; 95% CI: 1.29–3.44) and distant stages (HR, 6.17; 95% CI: 3.83–9.94) had a lower OS possibility, while surgery (HR, 0.39; 95% CI: 0.28–0.53) and history of malignancy (HR, 0.68; 95% CI: 0.48–0.98) was protective factors for PSCC. PSCC survived longer with surgery performed instead of chemotherapy or radiotherapy.ConclusionsPatients of PSCC have a poor prognosis, and using the nomogram developed by this study can predict their 1-, 3- and 5-year OS probability. Surgery is a better choice for PSCC and more studies are necessary to find potential treatment like targeted therapy, programmed death-1 (PD-1) and programmed death ligand 1 (PD-L1).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.